Caladrius Takes Former Baxalta Angina Program Off Shire's Hands
Executive Summary
Shire has divested a cell therapy program for angina it picked up via the acquisition of Baxalta in 2016; Caladrius hopes to bring the Phase III treatment to the US market soon.
You may also be interested in...
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.